EUVIMEDEUVIMED entdecken
Crossref

Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes

Zhen-Lin Tan, Chen Liu, Jia-Yu Huang, Dan Wu, Zheng Feng, Jing Xue, Yan Liao, Yi-Yao Zhu, Yu Zhao, Dong-Hui Lu

World Journal of Diabetes · 16.11.2026

DOI: 10.4239/wjd.125659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Diabetes, online erschienen am 16.11.2026. Verfasst von Zhen-Lin Tan und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUNDDiabetes mellitus is a global epidemic primarily driven by pancreatic β-cell dysfunction.Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for diabetes, yet their underlying mechanisms remain incompletely understood.The circular RNA ciRS-7 (CDR1as) sponges miR-7, a negative regulator of β-cell function, affecting downstream targets Myrip and Pax6.However, whether MSC treatment is associated with this axis is unknown. AIMTo investigate whether MSC treatment is associated with modulation of the ciRS-7/miR-7/Myrip/Pax6 axis and with changes in β-cell function in diabetes. METHODSIn vitro, in INS-1 β-cells, ciRS-7 was silenced using specific siRNAs or overexpressed via plasmid transfection, followed by co-culture with MSCs.Cell Counting Kit-8 absorbance in the co-culture system, insulin levels in the culture supernatant (enzyme-linked immunosorbent assay), and expression of ciRS-7, miR-7, Myrip, and Pax6 (quantitative reverse transcription PCR/Western blot) were measured.In vivo, type 2 diabetes mellitus rats were treated with human umbilical cord MSCs (hUC-MSCs) or phosphate-buffered saline; blood glucose, intraperitoneal glucose tolerance test, pancreatic histology, β-cell ultrastructure, and molecular changes were evaluated. RESULTSIn vitro, MSC treatment was associated with increased total ciRS-7 in the co-culture system and insulin levels in the culture supernatant in a dose-dependent manner.ciRS-7 knockdown attenuated these MSC-associated effects, while ciRS-7 overexpression 4 / 40 enhanced them, along with reciprocal changes in miR-7, Myrip, and Pax6.In vivo, hUC-MSC treatment improved glycemic control and glucose tolerance and was associated with structural changes consistent with improved islet morphology, as well as upregulation of ciRS-7, Pax6, and Myrip and downregulation of miR-7. CONCLUSIONThese findings link MSC-based therapy to the ciRS-7/miR-7/Myrip/Pax6 axis.MSC treatment was associated with significant improvement in glycemic control and with changes in this axis.

Zitieren

APA

Tan, Z., Liu, C., Huang, J., Wu, D., Feng, Z., Xue, J., Liao, Y., Zhu, Y., Zhao, Y., & Lu, D. (2026). Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes. World Journal of Diabetes. https://doi.org/10.4239/wjd.125659

Vancouver

Tan Z, Liu C, Huang J, Wu D, Feng Z, Xue J, et al. Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes. World Journal of Diabetes. 2026. doi:10.4239/wjd.125659

BibTeX
@article{Tan2026,
  author = {Tan, Zhen-Lin and Liu, Chen and Huang, Jia-Yu and Wu, Dan and Feng, Zheng and Xue, Jing and Liao, Yan and Zhu, Yi-Yao and Zhao, Yu and Lu, Dong-Hui},
  title = {Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes},
  journal = {World Journal of Diabetes},
  year = {2026},
  doi = {10.4239/wjd.125659}
}
Kostenlos starten →